期刊文献+

大鼠血浆内甲磺酸伊马替尼浓度的测定及其药动学研究 被引量:3

Determination of imatinib mesylate in rat plasma and its pharmacokinetic study
下载PDF
导出
摘要 目的建立高效液相色谱法测定大鼠血浆中甲磺酸伊马替尼浓度,并研究其在大鼠体内的药物动力学。方法色谱柱为Dikma Diamonsil C18;流动相为甲醇-1%三乙醇胺溶液=55:45(pH=6);流速为1.0 mL min-1;柱温为30℃;检测波长285 nm;并用该液相方法测定伊马替尼在SD大鼠体内的药动学参数。结果伊马替尼血药浓度在20~2 000 ng mL-1线性关系良好(r=0.999 3),最低检测限为20 ng mL-1;日内、日间RSD均〈15%,提取回收率在82.1%~87.5%。6只SD大鼠单剂量静脉给予伊马替尼(10 mg kg-1)后药动学参数分别为:Cmax(1 567.4±127.5)ng mL-1;t1/2(15.6±3.5)h;MRT(17.9±4.6)h;Vd(27.3±6.9)L;AUC0~24 h(2 267.4±109.6)ng h mL-1;AUC0~∞(3 308.2±208.2)ng h mL-1。结论本方法简便、准确、灵敏、专属性强,可作为伊马替尼临床用药时的药动学数据补充。 Objective To develop a simple and sensitive HPLC-UV method to quantify imatinib in rat plasma. Methods The chromatographic separation was carried out on a Dikma Diamonsil C 18 column with a mobile phase consisting of methanol-1% TEA(55 :45, v/v, pH = 6) at 1.0 mL min- 1. The column temperature was 30 ℃. UV wavelength mode was used, with imatinib monitored at 285 nm. Results The calibration was linear at 20- 2 000 ng mL- 1for imatinib. Inter-day and intra-day imprecision was 15% for imatinib. The pharmacokinetic parameters were: C max(1 567.4±127.5) ng mL- 1;t 1/2(15.6±3.5) h;MRT(17.9±4.6) h;Vd(27.3±6.9) L;AUC0 ~ 24h(2 267.4±109.6) ng h mL- 1;AUC 0 ~ ∞(3 308.2±208.2) ng h mL- 1. Conclusion This simple, sensitive, accurate and cost-effective method can be used in routine clinical practice to monitor imatinib concentrations in the plasma.
作者 许勇 刘明达
出处 《中南药学》 CAS 2013年第11期818-820,共3页 Central South Pharmacy
关键词 伊马替尼 高效液相色谱法 药动学 imatinib HPLC pharmacokinetics
  • 相关文献

参考文献8

  • 1De Kogel CE, Sehellens JH. Imatinib [J]. Oneologist, 2007, 12 (12) : 1390-1394.
  • 2Ksienski D. Imatinib mesylate: past successes and future challen- ges in the treatment of gastrointestinal stromal tumors [J]. Clin Med InsightsOncol, 2011, 5 (1) : 365-379.
  • 3Teng JF, Mabasa VH, Ensom MH. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors [J]. TherDrugMonit, 2012, 34 (1) : 85-97.
  • 4Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels[J]. Curr Opin Oncol, 2010, 22 ( 4 ) : 336-341.
  • 5Petain A, Kattygnarath D, Azard J, et al. Population pharmaco- kinetics and pharmacogenetics of imatinib in children and adults [J]. ClinCancerRes, 2008, 14 (21) : 7102-7109.
  • 6Zhang M, Moore GA, Fernyhough LJ, et al. Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry [J]. Anal Bioanal Chem, 2012, 404 (6-7) : 2091-2096.
  • 7Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromato- graphy and ultraviolet detection [J]. J Chromatogr Sci, 2011, 49 (5) : 412-415.
  • 8王晨明,林高通,王哲,徐涛,胡国新.HPLC检测大鼠血浆中伊马替尼的浓度及其药动学研究[J].中国药学杂志,2013,48(4):293-296. 被引量:4

共引文献3

同被引文献35

  • 1陈敖,黄荷香,宋帅娟,陈小琴.甲磺酸伊马替尼的合成[J].精细与专用化学品,2007,15(8):23-25. 被引量:11
  • 2Awidi A,Salem II,Najib N, et al. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performanee liquid chromatography-ultraviolet detection and liquid chromatographytandem mass spectrometry: methods' comparison [J]. Leuk Res,2010,34(6) :714 -717.
  • 3Yeung DT, Osborn MP, White DL, et al. TIDEL-II : first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets [J]. Blood, 2015,125 (6) :915 -923.
  • 4Tan KL, Ankathil R, Gan SH. Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection [J]. J Chromatogr B Analyt Technol Biomed Life Sci,2011, 879(30) :3583 -3591.
  • 5Filppula AM, Laitila J, Neuvonen PJ, et al. Potent mechanismbased inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates [J]. Br J Pharmacol, 2012,165 (8) :2787 -2798.
  • 6Pirro E, De Francia S, De Martino F, et al. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients [J]. J Chromatogr Sci, 2011,49 (10) :753 -757.
  • 7Lin G, Wang C, Qiu x, et al. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat [J]. Drug Dev Ind Pharm,2014,40(12) :1616 - 1622.
  • 8Rezende VM, Rivellis A, Novaes MM, et al. Quantification of imatinib in human serum : validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmaeokinetic assays [J]. Drug Des Devel Ther,2013 (7) :699 - 710.
  • 9Ma S, Xu Y, Shou M. Characterization of imatinib metabolites in rat and human liver microsomes: differentiation of hydroxylation from N-oxidation by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry [J]. Rapid Commun Mass Speetrom,2009,23 (10) : 1446 - 1450.
  • 10Zhang Y, Qiang S, Yu Z, et al. LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma[J]. J Chromatogr Sei,2014,52(4) :344 -350.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部